Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.77
-0.40 (-1.42%)
Mar 5, 2026, 2:53 PM EST - Market open
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 47.17, with a low estimate of 40 and a high estimate of 52. The average target predicts an increase of 69.86% from the current stock price of 27.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $41 → $44 | Buy | Maintains | $41 → $44 | +58.44% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $43 → $47 | Strong Buy | Maintains | $43 → $47 | +69.25% | Jan 26, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $52 | Strong Buy | Maintains | $35 → $52 | +87.25% | Jan 12, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $30 → $43 | Strong Buy | Maintains | $30 → $43 | +54.84% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 → $50 | Strong Buy | Maintains | $37 → $50 | +80.05% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
351.46M
from 344.23M
Increased by 2.10%
Revenue Next Year
395.86M
from 351.46M
Increased by 12.63%
EPS This Year
-1.19
from -0.83
EPS Next Year
-0.59
from -1.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 365.4M | 410.0M | |||
| Avg | 351.5M | 395.9M | |||
| Low | 330.8M | 376.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.1% | 16.7% | |||
| Avg | 2.1% | 12.6% | |||
| Low | -3.9% | 7.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.83 | -0.19 | |||
| Avg | -1.19 | -0.59 | |||
| Low | -1.40 | -0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.